A5080673678- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Complement system in diseases
- Blood groups and transfusion
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Renal Diseases and Glomerulopathies
- T-cell and B-cell Immunology
- Platelet Disorders and Treatments
- Cytomegalovirus and herpesvirus research
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- DNA Repair Mechanisms
Hôpital Saint-Louis
2016-2025
Université Paris Cité
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Délégation Paris 7
2015-2024
Inserm
2014-2024
Sorbonne Paris Cité
2012-2024
European Society for Blood and Marrow Transplantation
2015-2024
National Heart Lung and Blood Institute
2009-2024
National Institutes of Health
2009-2024
European Society for Blood and Marrow Transplantation
2015-2024
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT 43,581 patients, comprising 19,798 (41%) allogeneic 28,714 (59%) autologous, reported by 700 centers 51 during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid 27,895 (64%), nonmalignant disorders 3173 (7%). A marked growth CAR-T cellular therapies from 151 2017 1134 patients 2019 is observed. This year's analyses focus on changes over 30 years....
Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas.On behalf the Société Française de Greffe Moëlle et Thérapie Cellulaire, we conducted retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral not otherwise specified (PTCL-NOS; angioimmunoblastic (AITL; 11),...
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based clinical and scientific developments in field. This is eighth special report HCT haematological diseases, solid tumours immune disorders. Our aim to provide general guidance according prevailing countries centres. In order inform patient decisions, these must be considered conjunction with risk of disease, procedure non-transplant strategies, including...
Eculizumab, a humanized monoclonal antibody against complement protein C5 that inhibits terminal activation, has been shown to prevent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve quality life overall survival, but data on the use eculizumab in women during pregnancy are scarce.
A single-group, phase 1-2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.In this prospective, investigator-led, open-label, multicenter, randomized, 3 trial, we compared and safety ATG or without as front-line previously untreated anemia. The primary end point was a hematologic complete response at months.Patients were assigned to receive (Group...
Abstract Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants performed in Europe associated countries continues to rise with 47,468 HCT 42,901 patients [19,630 allogeneic (41%) 27,838 autologous (59%)] reported by 701 centers 50 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid 27,318 (64%; 20% solid tumors 1625 (4%; 2.9% nonmalignant 3063 (7%; 81% allogeneic). This...
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants done in Europe associated countries continues to rise with 45,418 HCT 41,100 patients [(17,155 allogeneic (42%) 23,945 autologous (58%)] reported by 683 centers 50 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid 26,488 (64%; 19% solid tumors 1,607 (3.9%; 2% nonmalignant 2,667 (7%; 81% allogeneic). Trends donor...
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries individual centers. In 2016, 82,718 first HCT were reported 1,662 teams in 86 195 World Health Organization states representing a global increase 6.2% autologous 7.0% allogeneic bringing total to 1,298,897 procedures. Assuming frequency 84,000/year, 1.5 million performed 2019...
Abstract In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 received advanced cellular therapies, 2524 of which CAR-T treatments, an additional 3245 DLI. Changes compared to the previous year treatment (+35%), +5.4%, autologous +3.9%, more pronounced non-malignant disorders. Main indications for myeloid malignancies 10,745 (58%), lymphoid 5127 (28%) disorders 2501 (13%). 22,129 (90%) solid tumors 1635 (7%)....
BackgroundPersistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or not complement inhibitors. Iptacopan, first-in-class factor B inhibitor, has been shown to improve hemoglobin levels in these patients.MethodsIn two phase 3 trials, we assessed iptacopan monotherapy over 24-week period less than 10 g per deciliter. In the first, anti-C5–treated were randomly assigned switch continue...
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis leading to anemia, fatigue, and potentially life-threatening thrombotic complications. Breakthrough (BTH) was first described in patients with PNH treated terminal complement C5 inhibitors when reoccurred despite treatment. Pegcetacoplan, the proximal C3 inhibitor, offers broad control PNH. While experience of managing BTH on documented, very limited guidance exists for inhibitors. This...
Pegcetacoplan significantly improves outcomes for patients with paroxysmal nocturnal hemoglobinuria (PNH) experiencing extravascular hemolysis (EVH) on eculizumab, leading to approval in 2021/2022 (USA/Europe). We report the first collaborative real-world evidence pegcetacoplan use UK and France. A total of 48 were either currently receiving or previously received (2019-2023). 12 had participated PEGASUS clinical trial, continuing treatment after trial completion. Five combination C5...
Abstract Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), identification of variables associated with response without is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by diversity between two given alleles same gene, may be a factor. A retrospective multicenter...
We explored the feasibility of unrelated donor haematopoietic stem cell transplant (HSCT) upfront without prior immunosuppressive therapy (IST) in paediatric idiopathic severe aplastic anaemia (SAA). This cohort was then compared to matched historical controls who had undergone first-line with a sibling/family (MSD) HSCT (n = 87) or IST horse antithymocyte globulin and ciclosporin 58) second-line post-failed 24). The 2-year overall survival 96 ± 4% 91 3% MSD (P 0·30) 94 0·68) 74 9% post-IST...